Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $1.67 0.3176 +23.53%
GALT $2.20 0.2400 +12.24%
CTIX $1.95 0.1900 +10.80%
OGXI $2.93 0.2500 +9.33%
CERU $4.12 0.3400 +8.99%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PARD $0.08 -0.1100 -57.89%
FATE $6.60 -0.6110 -8.47%
SRNE $12.78 -0.8700 -6.37%
ARIA $9.30 -0.5900 -5.97%
GERN $3.04 -0.1900 -5.88%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

American Cancer Society and MyLifeLine.org Partner To Provide Cancer Focused Social Support Services

(ACS) Aug 18, 2015 - The American Cancer Society and MyLifeLine.org Cancer Foundation (MyLifeLine.org) are pleased to announce a new partnership to provide social and emotional support services to all people affected by cancer.
read press release 



Intel Launches a Network To Enable Personalized Cancer Treatments

(VentureBeat) Aug 19, 2015 - It took 23 years of treatment and an extended search for a cure to treat Eric Dishman's cancer.
read article 



Paradigm Announces Molecular Profiling Collaboration for Study of Altiratinib In Genomically Defined Cancer Patients

(MarketWatch) Aug 19, 2015 - Paradigm today announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, gastric cancer, renal cancer, and glioblastoma multiforme (GBM).
read article 



Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer

(StreetInsider) Aug 20, 2015 - Pfizer Inc. today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE® (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.
read article 



Former President Jimmy Carter Says Cancer Has Spread To His Brain

(Washington Post) Aug 20, 2015 - Former president Jimmy Carter said that the cancer doctors discovered earlier this year, on his liver, has spread to his brain and that he will receive his first radiation treatment for the disease Thursday afternoon.
read article (free registration) 



Has the Choosing Wisely Campaign Affected Clinical Oncology Practice?

(Medscape Oncology) Aug 19, 2015 - The aim of the Choosing Wisely initiative, launched in 2012 by the ABIM Foundation, is to encourage providers and patients to follow evidence-based treatment regimens and to cease performing tests and procedures that probably provide no benefit and contribute to healthcare spending in the United States.
read article (free registration required) 



'Thousands' Denied Life-Extending Cancer Tests

(Sky News [UK]) Aug 20, 2015 - Thousands of cancer patients in England are missing out on targeted drugs because they are not being offered tests to identify genetic faults underpinning the cause of their cancer, according to a charity.
read article 



New Guidelines To Help Payers Navigate NGS Testing in Cancer

(Medscape Medical News) Aug 19, 2015 - Next-generation sequencing (NGS) technologies enable the rapid generation of data by their ability to sequence massive amounts of DNA in parallel, using diverse methodologies.
read article (free registration required) 



Paxman Cold Cap Chemotherapy Hair Loss Prevention Investigational Device - Clinical Trials Expand To Second Dallas Oncology Center

(Yahoo! Finance) Aug 19, 2015 - The U.S. clinical trials of a UK developed hair loss prevention system for early stage breast cancer patients have been expanded to an additional US Oncology Research site in Dallas.
read article 



Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination with Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers

(Yahoo! Finance) Aug 20, 2015 - Advaxis, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, today announced that enrollment has commenced in a Phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy.
read article 



Imaging Probe Outperforms the Best External Detector for Early Cervical Cancer

(ICR [UK]) Aug 20, 2015 - An endovaginal magnetic resonance imaging technique is more accurate at detecting early-stage cervical cancer than the best widely available method, a new study reports.
read article 



An Easy Pairing

(Fred Hutch) Aug 19, 2015 - Fred Hutch's Harlan Robins develops a new method to match thousands of pairs of key genes needed for cancer immunotherapy.
read article 



Lynparza Improves Overall Survival in High-Risk Gastric Cancer

(MedPage Today) Aug 19, 2015 - The combination of olaparib (Lynparza) and paclitaxel was active in patients with metastatic gastric cancer, with an overall survival (OS) benefit relative to paclitaxel alone in patients with low or undetectable levels of a DNA damage response gene known as ATM, researchers said.
read article (free registration required) 



Study: Fewer Moles May Mean More Aggressive Melanoma

(American Academy of Dermatology) Aug 20, 2015 - People with more than 50 moles have an increased risk of developing melanoma, the deadliest form of skin cancer, but those with fewer than 50 moles should still be alert for this disease.
read press release 



Early-Stage Breast Condition May Not Require Cancer Treatment

(New York Times) Aug 20, 2015 - As many as 60,000 American women each year are told they have a very early stage of breast cancer — Stage 0, as it is commonly known — a possible precursor to what could be a deadly tumor.
read article 



New Kind of Cancer Study Finds New Targets for Tailored Treatments

(NBC News) Aug 20, 2015 - A new kind of cancer study supports the idea that traditional treatment can be turned on its head, with patients given targeted therapy based not on where their tumors started but on their own genetic mutations.
read article 



Memorial Sloan Kettering Cancer Center Researchers Publish Landmark “Basket Study”

(MSK) Aug 19, 2015 - Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
read press release 



Novartis Drug Odomzo® Gains EU Approval for Locally Advanced Basal Cell Carcinoma, Providing New Non-Invasive Therapy for Patients

(MarketWatch) Aug 20, 2015 - Novartis announced today that the European Commission has approved Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.
read article 



Black Women Less Likely to Survive Uterine Cancer

(WebMD/HealthDay News) Aug 19, 2015 - Uterine cancer rates are rising in the United States, particularly among black and Asian women, according to a new study that also found black women are more likely to die of the disease.
read article 



The NCI Community Cancer Centers Program Has Positive Impact in Nebraska

(ASCO in Action) Aug 19, 2015 - A new study published on August 11 in the Journal of Oncology Practice demonstrates the feasibility of a National Cancer Institute (NCI) program to advance cancer research and improve quality of care in a rural community setting.
read article 



Lundbeck Surges as New CEO Cuts 17% of Jobs to Fight Generics

(Bloomberg) Aug 19, 2015 - H. Lundbeck A/S shares surged as Chief Executive Officer Kaare Schultz, just three months on the job, said he’ll cut about 17 percent of the workforce as the drugmaker fights generic competition.
read article 



Roche Snaps Up Gene Sequencing Group Kapa

(PharmaTimes [UK]) Aug 19, 2015 - Roche is pulling private gene-sequencing firm Kapa Biosystems under its wing for an undisclosed amount in a move to ramp up its offering in next-generation sequencing.
read article 



FDA Warns Mylan About Violations At Indian Plants

(Pittsburgh Post-Gazette) Aug 18, 2015 - The U.S. Food and Drug Administration cited local generic drug giant Mylan for "significant violations" of manufacturing regulations at three plants in India, according to a warning letter released by the agency.
read article 



Amgen to Pay $71 Million To States For Promoting Off-Label Drug Uses

(Los Angeles Times) Aug 18, 2015 - Amgen Inc. has agreed to pay $71 million to settle allegations by 48 state attorneys general that it improperly marketed two of its blockbuster drugs.
read article (free registration required) 



FDA Approves Controversial ‘Little Pink Pill’ But With Restrictions

(MSNBC/NBCNews.com) Aug 19, 2015 - The Food and Drug Administration has approved a pill that aims to increase a woman’s desire for sex — a controversial decision made only after an extended lobbying campaign by the drug’s makers.
read article